165 related articles for article (PubMed ID: 36499211)
21. Dual inhibition of Met kinase and angiogenesis to overcome HGF-induced EGFR-TKI resistance in EGFR mutant lung cancer.
Takeuchi S; Wang W; Li Q; Yamada T; Kita K; Donev IS; Nakamura T; Matsumoto K; Shimizu E; Nishioka Y; Sone S; Nakagawa T; Uenaka T; Yano S
Am J Pathol; 2012 Sep; 181(3):1034-43. PubMed ID: 22789825
[TBL] [Abstract][Full Text] [Related]
22. Cytotoxic effects of 15-deoxy-Δ12,14-prostaglandin J2 alone and in combination with dasatinib against uterine sarcoma
Kawakita T; Masato N; Takiguchi E; Abe A; Irahara M
Exp Ther Med; 2017 Jun; 13(6):2939-2945. PubMed ID: 28587364
[TBL] [Abstract][Full Text] [Related]
23. KRC-408, a novel c-Met inhibitor, suppresses cell proliferation and angiogenesis of gastric cancer.
Hong SW; Jung KH; Park BH; Zheng HM; Lee HS; Choi MJ; Yun JI; Kang NS; Lee J; Hong SS
Cancer Lett; 2013 May; 332(1):74-82. PubMed ID: 23348694
[TBL] [Abstract][Full Text] [Related]
24. SRJ09, a promising anticancer drug lead: Elucidation of mechanisms of antiproliferative and apoptogenic effects and assessment of in vivo antitumor efficacy.
Wong CC; Lim SH; Sagineedu SR; Lajis NH; Stanslas J
Pharmacol Res; 2016 May; 107():66-78. PubMed ID: 26940565
[TBL] [Abstract][Full Text] [Related]
25. Autophagy inhibitor potentiates the antitumor efficacy of apatinib in uterine sarcoma by stimulating PI3K/Akt/mTOR pathway.
Chen S; Yao L
Cancer Chemother Pharmacol; 2021 Aug; 88(2):323-334. PubMed ID: 33978839
[TBL] [Abstract][Full Text] [Related]
26. Lysosomal accumulation of drugs in drug-sensitive MES-SA but not multidrug-resistant MES-SA/Dx5 uterine sarcoma cells.
Wang E; Lee MD; Dunn KW
J Cell Physiol; 2000 Aug; 184(2):263-74. PubMed ID: 10867652
[TBL] [Abstract][Full Text] [Related]
27. Different effects of magnetic field on drug activity in human uterine sarcoma cell lines MES-SA and MES-SA/Dx5.
Shibaki R; Kakikawa M
Electromagn Biol Med; 2022 Jul; 41(3):343-351. PubMed ID: 35793396
[TBL] [Abstract][Full Text] [Related]
28. ANTIPSYCHOTICS REVERSE P-GLYCOPROTEIN-MEDIATED DOXORUBICIN RESISTANCE IN HUMAN UTERINE SARCOMA MES-SA/Dx5 CELLS: A NOVEL APPROACH TO CANCER CHEMOTHERAPY.
Angelini A; Ciofani G; Conti P
J Biol Regul Homeost Agents; 2015; 29(2):357-65. PubMed ID: 26122223
[TBL] [Abstract][Full Text] [Related]
29. PGRMC1 contributes to doxorubicin-induced chemoresistance in MES-SA uterine sarcoma.
Lin ST; May EW; Chang JF; Hu RY; Wang LH; Chan HL
Cell Mol Life Sci; 2015 Jun; 72(12):2395-409. PubMed ID: 25596698
[TBL] [Abstract][Full Text] [Related]
30. Histone deacetylase inhibitor vorinostat suppresses the growth of uterine sarcomas in vitro and in vivo.
Hrzenjak A; Moinfar F; Kremser ML; Strohmeier B; Petru E; Zatloukal K; Denk H
Mol Cancer; 2010 Mar; 9():49. PubMed ID: 20202195
[TBL] [Abstract][Full Text] [Related]
31. Proteomic analysis of proteins responsible for the development of doxorubicin resistance in human uterine cancer cells.
Lin ST; Chou HC; Chang SJ; Chen YW; Lyu PC; Wang WC; Chang MD; Chan HL
J Proteomics; 2012 Oct; 75(18):5822-47. PubMed ID: 22889595
[TBL] [Abstract][Full Text] [Related]
32. Combined therapy with mutant-selective EGFR inhibitor and Met kinase inhibitor for overcoming erlotinib resistance in EGFR-mutant lung cancer.
Nakagawa T; Takeuchi S; Yamada T; Nanjo S; Ishikawa D; Sano T; Kita K; Nakamura T; Matsumoto K; Suda K; Mitsudomi T; Sekido Y; Uenaka T; Yano S
Mol Cancer Ther; 2012 Oct; 11(10):2149-57. PubMed ID: 22844075
[TBL] [Abstract][Full Text] [Related]
33. The acridonecarboxamide GF120918 potently reverses P-glycoprotein-mediated resistance in human sarcoma MES-Dx5 cells.
Traunecker HC; Stevens MC; Kerr DJ; Ferry DR
Br J Cancer; 1999 Nov; 81(6):942-51. PubMed ID: 10576649
[TBL] [Abstract][Full Text] [Related]
34. Wnt5A regulates ABCB1 expression in multidrug-resistant cancer cells through activation of the non-canonical PKA/β-catenin pathway.
Hung TH; Hsu SC; Cheng CY; Choo KB; Tseng CP; Chen TC; Lan YW; Huang TT; Lai HC; Chen CM; Chong KY
Oncotarget; 2014 Dec; 5(23):12273-90. PubMed ID: 25401518
[TBL] [Abstract][Full Text] [Related]
35. Monitoring incorporation, transformation and subcellular distribution of N-l-leucyl-doxorubicin in uterine sarcoma cells using capillary electrophoretic techniques.
Wang Y; Arriaga EA
Cancer Lett; 2008 Apr; 262(1):123-32. PubMed ID: 18194838
[TBL] [Abstract][Full Text] [Related]
36. Euphorbiasteroid reverses P-glycoprotein-mediated multi-drug resistance in human sarcoma cell line MES-SA/Dx5.
Choi JS; Kang NS; Min YK; Kim SH
Phytother Res; 2010 Jul; 24(7):1042-6. PubMed ID: 19960428
[TBL] [Abstract][Full Text] [Related]
37. Combined targeting of mTOR and c-MET signaling pathways for effective management of epithelioid sarcoma.
Imura Y; Yasui H; Outani H; Wakamatsu T; Hamada K; Nakai T; Yamada S; Myoui A; Araki N; Ueda T; Itoh K; Yoshikawa H; Naka N
Mol Cancer; 2014 Aug; 13():185. PubMed ID: 25098767
[TBL] [Abstract][Full Text] [Related]
38. Inhibition of uterine sarcoma cell growth through suppression of endogenous tyrosine kinase B signaling.
Makino K; Kawamura K; Sato W; Kawamura N; Fujimoto T; Terada Y
PLoS One; 2012; 7(7):e41049. PubMed ID: 22911740
[TBL] [Abstract][Full Text] [Related]
39. Epigenetic silencing of apoptosis-inducing gene expression can be efficiently overcome by combined SAHA and TRAIL treatment in uterine sarcoma cells.
Fröhlich LF; Mrakovcic M; Smole C; Lahiri P; Zatloukal K
PLoS One; 2014; 9(3):e91558. PubMed ID: 24618889
[TBL] [Abstract][Full Text] [Related]
40. Modulation of multidrug resistance p-glycoprotein activity by flavonoids and honokiol in human doxorubicin- resistant sarcoma cells (MES-SA/DX-5): implications for natural sedatives as chemosensitizing agents in cancer therapy.
Angelini A; Di Ilio C; Castellani ML; Conti P; Cuccurullo F
J Biol Regul Homeost Agents; 2010; 24(2):197-205. PubMed ID: 20487633
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
